Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

The Lancet Microbe 2026 Open access

Read full text
Authors: Onyema Ogbuagu, Aditya Gaur, James H McMahon, Linda Gorgos, Javier O Morales-Ramirez, Kimberly Workowski, Jason Brunetta, Kwad Mponponsuo, Sean E Collins, Laurie A. VanderVeen, Nan Zhang, Hailin Huang
+2 more Jared M. Baeten, Joseph Eron
DOI: 10.1016/j.lanmic.2025.101283
Cited by: 6
References: 27

Abstract

BACKGROUND: In a phase 1b study (NCT04811040), lenacapavir combined with the broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab maintained virological suppression (HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment Hepatitis C virus research Virus-based gene therapy research

Publication details

Journal / source
The Lancet Microbe
Publisher
Elsevier BV
Volume
7
Issue
3
Pages
101283–101283
Publication date
17 February 2026
Language
EN